- 4-Week # shares sold: 4,401
- 12-Week # shares sold: 15,486
- 24-Week # shares sold: 54,524
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Here are Tuesday's top research calls, including upgrades for Biogen and Caterpillar, and increased price targets for Apple and Micron.